Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 656

1.

Induction of gp120-specific protective immune responses by genetic vaccination with linear polyethylenimine-plasmid complex.

Garzón MR, Berraondo P, Crettaz J, Ochoa L, Vera M, Lasarte JJ, Vales A, Van Rooijen N, Ruiz J, Prieto J, Zulueta J, González-Aseguinolaza G.

Vaccine. 2005 Feb 3;23(11):1384-92.

PMID:
15661387
3.

Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.

Abaitua F, Rodríguez JR, Garzón A, Rodríguez D, Esteban M.

Virus Res. 2006 Mar;116(1-2):11-20. Epub 2005 Oct 7.

PMID:
16214252
4.

Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein.

Kaneko H, Bednarek I, Wierzbicki A, Kiszka I, Dmochowski M, Wasik TJ, Kaneko Y, Kozbor D.

Virology. 2000 Feb 1;267(1):8-16.

5.

DNA vaccine expressing HIV-1 gp120/immunoglobulin fusion protein enhances cellular immunity.

Shimada M, Yoshizaki S, Jounai N, Kondo A, Ichino M, Ryo A, Okuda K.

Vaccine. 2010 Jul 12;28(31):4920-7. doi: 10.1016/j.vaccine.2010.05.035. Epub 2010 Jun 3.

PMID:
20566393
6.

HIV-1 DNA vaccine efficacy is enhanced by coadministration with plasmid encoding IFN-alpha.

Jiang W, Ren L, Jin N.

J Virol Methods. 2007 Dec;146(1-2):266-73. Epub 2007 Sep 14.

PMID:
17868910
9.

Topical application of HIV DNA vaccine with cytokine-expression plasmids induces strong antigen-specific immune responses.

Liu LJ, Watabe S, Yang J, Hamajima K, Ishii N, Hagiwara E, Onari K, Xin KQ, Okuda K.

Vaccine. 2001 Oct 12;20(1-2):42-8.

PMID:
11567744
10.

Polygene DNA vaccine induces a high level of protective effect against HIV-vaccinia virus challenge in mice.

Shinoda K, Xin KQ, Jounai N, Kojima Y, Tamura Y, Okada E, Kawamoto S, Okuda K, Klinman D, Okuda K.

Vaccine. 2004 Sep 9;22(27-28):3676-90.

PMID:
15315847
11.
12.

Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit.

Barnett SW, Rajasekar S, Legg H, Doe B, Fuller DH, Haynes JR, Walker CM, Steimer KS.

Vaccine. 1997 Jun;15(8):869-73.

PMID:
9234536
13.
14.

[Intranasal priming with HIV DNA vaccine and systemic boosting with recombinant vaccinia induce vigorous immune responses: experiment with mice].

Huang XG, Xu JQ, Ren L, Qiu C, Zhang N, Liu LX, Wan YM, Peng H, Shao YM.

Zhonghua Yi Xue Za Zhi. 2006 Nov 28;86(44):3109-13. Chinese.

PMID:
17313761
15.

Anti-HIV env immunities elicited by nucleic acid vaccines.

Shiver JW, Davies ME, Yasutomi Y, Perry HC, Freed DC, Letvin NL, Liu MA.

Vaccine. 1997 Jun;15(8):884-7.

PMID:
9234539
17.
18.

Novel engineered HIV-1 East African Clade-A gp160 plasmid construct induces strong humoral and cell-mediated immune responses in vivo.

Muthumani K, Zhang D, Dayes NS, Hwang DS, Calarota SA, Choo AY, Boyer JD, Weiner DB.

Virology. 2003 Sep 15;314(1):134-46.

19.
20.

Mucosal DNA vaccination with highly attenuated Shigella is superior to attenuated Salmonella and comparable to intramuscular DNA vaccination for T cells against HIV.

Vecino WH, Morin PM, Agha R, Jacobs WR Jr, Fennelly GJ.

Immunol Lett. 2002 Jul 3;82(3):197-204. Erratum in: Immunol Lett. 2004 Feb 15;91(2-3):256.

PMID:
12036602

Supplemental Content

Support Center